Why the study?
Do hybrid interventions (TAVR+OP/MIDCAB) provide comparable long-term outcomes to TAVR+PCI in patients with significant coronary artery disease undergoing aortic valve interventions?
Do hybrid interventions (TAVR+OP/MIDCAB) provide comparable long-term outcomes to TAVR+PCI in patients with significant coronary artery disease undergoing aortic valve interventions?
Hybrid interventions (TAVR+OP/MIDCAB) are reasonable second-line options for patients with significant CAD undergoing aortic valve interventions who are ineligible for SAVR+CABG and TAVR+PCI.
Answers are grounded in this paper and cite their sources.
Hybrid approaches may merit evaluation in select ineligible patients; leaves open need for randomized comparisons to TAVR+PCI.
TAVR+OP/MIDCAB patients share many characteristics with TAVR+PCI patients, with only slightly poorer long-term outcomes. In patients ineligible for SAVR+CABG and TAVR+PCI, hybrid interventions are reasonable second-line options.
No takes yet. Share an insight, caveat, or question.
Baumbach et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: